These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8424410)

  • 1. Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin > or = 100 mg/m2.
    Kris MG; Clark RA; Tyson LB; Hahne WF; Pisters KM; Gralla RJ
    Am J Clin Oncol; 1993 Feb; 16(1):77-80. PubMed ID: 8424410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
    Cheirsilpa A; Ratanatharathorn V; Sinlarat P; Chindavijak K; Lousoontornsiri W; Chakrapee-Sirisuk S; Srimuninimit V
    J Med Assoc Thai; 1994 Apr; 77(4):201-6. PubMed ID: 7844494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
    Hainsworth JD; Hesketh PJ
    Semin Oncol; 1992 Dec; 19(6 Suppl 15):14-9. PubMed ID: 1485176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis.
    Grunberg SM; Lane M; Lester EP; Sridhar KS; Mortimer J; Murphy W; Sanderson PE
    Cancer Chemother Pharmacol; 1993; 32(4):268-72. PubMed ID: 8324868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
    Beck TM; Hesketh PJ; Madajewicz S; Navari RM; Pendergrass K; Lester EP; Kish JA; Murphy WK; Hainsworth JD; Gandara DR
    J Clin Oncol; 1992 Dec; 10(12):1969-75. PubMed ID: 1453211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
    Ahn MJ; Lee JS; Lee KH; Suh C; Choi SS; Kim SH
    Am J Clin Oncol; 1994 Apr; 17(2):150-6. PubMed ID: 8141107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
    Navari RM; Madajewicz S; Anderson N; Tchekmedyian NS; Whaley W; Garewal H; Beck TM; Chang AY; Greenberg B; Caldwell KC
    J Clin Oncol; 1995 Sep; 13(9):2408-16. PubMed ID: 7666101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
    Kris MG; Tyson LB; Clark RA; Gralla RJ
    Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy.
    Sledge GW; Einhorn L; Nagy C; House K
    Cancer; 1992 Nov; 70(10):2524-8. PubMed ID: 1423181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral ondansetron and intravenous dexamethasone in the prevention of cisplatin-induced emesis. A phase II trial in women.
    Franchi M; Donadello N; Zanaboni F; Tusei A; Scorbati E
    Oncology; 1995; 52(6):509-12. PubMed ID: 7478441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial].
    Zeng WY
    Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):273-5. PubMed ID: 1396075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin].
    Suminaga M; Furue H; Taguchi T; Ota K; Niitani H; Tsukagoshi S; Ariyoshi Y; Ikeda M; Ohta J; Akasaka Y
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1333-45. PubMed ID: 1386975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin].
    Suminaga M; Furue H; Taguchi T; Niitani H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1879-90. PubMed ID: 1387774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group.
    Seynaeve C; Schuller J; Buser K; Porteder H; Van Belle S; Sevelda P; Christmann D; Schmidt M; Kitchener H; Paes D
    Br J Cancer; 1992 Jul; 66(1):192-7. PubMed ID: 1386245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination.
    Roila F
    Oncology; 1993; 50(3):163-7. PubMed ID: 8459986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis.
    Pectasides D; Mylonakis A; Varthalitis J; Kostopoulou M; Constantinou A; Papazachariou K; Antoniou F; Dimitriadis M; Athanassiou A
    Oncology; 1997; 54(1):1-6. PubMed ID: 8978584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy. French Ondansetron Study Group.
    Fumoleau P; Giovannini M; Rolland F; Votan B; Paillarse JM
    Oral Oncol; 1997 Sep; 33(5):354-8. PubMed ID: 9415336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.